rich 1.0 Episode 2 of OT Roundup is here. Lucia Gambuzza and co-host Veeral Sheth, MD, break down 4-year durability data for MOGENRY in retinitis pigmentosa, RCA's first State of Retina Care report, the FDA's upcoming review of SYD-101 for pediatric myopia, and new Phase 2 data on OCU410 for geographic atrophy. MOGENRY 4-year data: https://www.ophthalmologytimes.com/view/retina-society-2026-mco-010-optogenetic-therapy-maintains-visual-acuity-gains-through-4-years-in-advanced-rp RCA's State of Retina Care report: https://www.ophthalmologytimes.com/view/rca-releases-first-state-of-retina-care-report FDA Advisory Committee on SYD-101: https://www.ophthalmologytimes.com/view/fda-advisory-committee-syd-101-pediatric-myopia-october-30 Nimesh Patel, MD on pediatric progressive myopia: https://www.ophthalmologytimes.com/view/pediatric-progressive-myopia-epidemic-permanent-vision-loss (https://www.ophthalmologytimes.com/view/nimesh-patel-md-on-low-dose-atropine-syd-101) OCU410 Phase 2 data: https://www.ophthalmologytimes.com/view/retina-society-2026-medium-dose-ocu410-gene-therapy-cuts-geographic-atrophy-progression-up-to-32-in-phase-2-trial EyePod https://audioboom.com/channels/5025218-eyepod Audioboom https://audioboom.com 480 95 https://audioboom.com/i/43862726/600x600/c 600 600 <iframe width="100%" height="95" src="https://embeds.audioboom.com/posts/8959099/embed?v=202301" style="background-color: transparent; display: block; padding: 0; width: 100%" frameborder="0" allowtransparency="allowtransparency" scrolling="no" title="Audioboom player" allow="autoplay" sandbox="allow-downloads allow-forms allow-popups allow-same-origin allow-scripts allow-storage-access-by-user-activation allow-top-navigation-by-user-activation"></iframe>